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Mesenchymal stem cells (MSC) represent a heterogeneous population exhibiting stem cell-like properties which are
distributed almost ubiquitously among perivascular niches of various human tissues and organs. Organismal
requirements such as tissue damage determine interdisciplinary functions of resident MSC including self-renewal,
migration and differentiation, whereby MSC support local tissue repair, angiogenesis and concomitant
immunomodulation. However, growth of tumor cells and invasion also causes local tissue damage and injury which
subsequently activates repair mechanisms and consequently, attracts MSC. Thereby, MSC exhibit a tissue-specific
functional biodiversity which is mediated by direct cell-to-cell communication via adhesion molecule signaling and
by a tightly regulated exchange of a multifactorial panel of cytokines, exosomes, and micro RNAs. Such interactions
determine either tumor-promoting or tumor-inhibitory support by MSC. Moreover, fusion with necrotic/apoptotic
tumor cell bodies contributes to re-program MSC into an aberrant phenotype also suggesting that tumor tissue in
general represents different types of neoplastic cell populations including tumor-associated stem cell-like cells. The
present work summarizes some functional characteristics and biodiversity of MSC and highlights certain
controversial interactions with normal and tumorigenic cell populations, including associated modulations within
the MSC microenvironment.
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Mesenchymal stem cells (MSC) can be identified in and
isolated from nearly all kinds of human tissues. MSC are
often synonymously termed stromal cells while other
reports distinguish MSC as a precursor of stromal cells.
As firstly described, bone marrow-derived human MSC
(BM-hMSC) still represent the most frequently investi-
gated hMSC population to compare their properties to
those of other tissue-originating hMSC populations [1].
Among these are hMSC from adipose tissue [2], periph-
eral blood [3], heart [4], and lung [5] but more recently,
special attention was also given to hMSC obtained from
a variety of different neonatal tissues. These post-natal
tissues represent a useful ethically non-controversial al-
ternative providing certain advantages as a consistent* Correspondence: hass.ralf@mh-hannover.de
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reproduction in any medium, provided the orand enriched MSC source which is easily accessible.
These tissues include MSC from the amniotic fluid [6],
amniotic membrane [7-9], chorionic membrane [10],
chorionic villi [11], decidua [10], whole placenta [12,13],
cord blood [14], Wharton's jelly [15] and whole umbil-
ical cord (UC-MSC) [16].Proliferative capacity of MSC
The hMSC originating from different human tissues or
organs are designated as stem/stromal or stem-like cells
since they share functional properties such as continu-
ous cell cycle progression and plasticity by the capability
to differentiate at least along the mesodermal lineage.
However, several tissue-originating MSC display signifi-
cant differences in their proliferative capacities. Accord-
ing to the tissue-specific microenvironment of the
diverse MSC populations, UC-MSC exhibit a higher pro-
liferation potential than BM-MSC [17-19]. Thus, the
mean doubling time of the UC-MSC revealed about
24 h and remained almost constant for up to 10 cell pas-
sages. In contrast, the population doubling time of BM-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increased already after 6 cell passages [20]. Likewise, adi-
pose tissue-derived MSC also demonstrated an elevated
growth rate as compared to BM-MSC [21]. Morpho-
logical evaluations revealed a larger BM-MSC size in
contrast to adipose tissue-derived MSC which was also
accompanied by an earlier in vitro senescence of BM-
MSC [22]. However, the in vitro results of MSC may dra-
matically differ from the in vivo situation. In this context,
effects of the cellular microenvironment such as oxidative
stress and DNA damage clearly influence the proliferative
capacity and premature aging of the cells [23]. Indeed,
hMSC demonstrate enhanced proliferative potential in a
hypoxic microenvironment which is also paralleled by an
altered energy-consuming metabolism [24].
Differentiation capacity and markers of MSC
With respect to differentiation capacity, previous work
has demonstrated that MSC can acquire certain func-
tions associated with adipogenic, chondrogenic or osteo-
genic maturation [25-27]. This differentiation potential
of MSC supports local tissue-specific precursor cells of
damaged organs, since the amount of these precursor
cells to retrodifferentiate to a more undifferentiated
phenotype is often insufficient to cope with the cell re-
placement requirements of the injured tissues [28,29].
Some reports suggested the capability of distinct MSC
populations to differentiate along cell lineages of all
three germ layers as described for amniotic fluid-derived
hMSC and for a certain clonal subpopulation of
decidual-derived hMSC [6,30]. However, a trans-germ
line differentiation via ectodermal or endodermal
lineages including maturation into hepatocytes, cardio-
myocyte or neuronal phenotypes remains controversial
[31]. Nevertheless, the initially tissue- or organ-derived
cells harbor a heterogeneous population of mesenchymal
stromal cells with stem cell-like properties since a variety
of distinct subpopulations can be isolated from such an
entity by centrifugal counter flow elutriation. These iso-
lated MSC subpopulations exhibit different growth rates
and aging properties by quantification of senescence-
associated β-galactosidase expression [32,33]. This kind
of heterogeneity may also explain differences in the ac-
tivation status and alterations in cell biological proper-
ties and functions within the same hMSC population.
According to this cellular diversity, a panel of multiple
markers is required for the characterization of mesen-
chymal stem cells. Minimal criteria for all hMSC popula-
tions have been defined by the International Society for
Cellular Therapy to characterize multipotent mesenchy-
mal stem cells which include the capacity to plastic ad-
herence, differentiation potential (at least osteogenic,
chondrogenic and adipogenic) and expression of the cell
surface markers CD73, CD90 and CD105 [34]. Inaddition to the necessity of these three surface molecules
on hMSC, further criteria require the simultaneous
absence of a variety of other specific markers in-
cluding the monocytic CD14, the endothelial CD31,
the hematopoietic stem cell marker CD34 and the
lymphocyte CD45 surface antigen [3].
Although hMSC have a common minimal expression
marker profile of surface receptors, additional distinct
surface molecules and metabolic alterations can be
detected between different hMSC populations which
may determine their functional diversity within the dif-
ferent tissues. For example, umbilical cord-derived (UC)
hMSC and some adipose tissue-derived MSC express
significant levels of CD44 in contrast to bone-marrow-
derived (BM) hMSC. However, there are controversial
reports on CD44 expression in BM-hMSC which sug-
gested that the original BM-hMSC represent the CD44-
phenotype whereby CD44 expression is acquired in the
course of in vitro culture of BM-hMSC [32,35]. The
CD44 surface molecule is also termed as hyaluronan re-
ceptor which consists of several splice variants and binds
supramolecular structures of highly sulfated proteogly-
cans, enabling a link of several protein components in
close vicinity. Certain matrix-metalloproteinases (MMPs)
can associate with distinct isoforms of the transmembrane
glycoprotein CD44 which anchors the proteinase to
the cell surface. This CD44-MMP association mediates
reorganization of distinct extracellular matrix (ECM) com-
ponents or contributes to focus the proteinase activities
e.g. towards growth factor activation such as cleavage
of pro-heparan-binding epidermal growth factor (pro
HB-EGF) for the generation of soluble active sHB-
EGF [36]. A similar formation of this ternary growth
factor complex is also observed in young human
mammary epithelial cells in contrast to their aging
counterparts and derailed signaling in this pathway
can contribute to aging-associated breast cancer devel-
opment [37-40]. Therefore, specific functions of CD44
appear to be important for MSC functions in the highly
enriched glucose-aminoglycan environment of the um-
bilical cord or the adipogenic breast tissue but to lesser
extend in the bone marrow.
Further markers are proposed for MSC which
characterize at least a certain MSC subpopulation. Such
markers include Stro-1 identified in BM-MSC [41]. The
Stro-1+ BM-MSC can inhibit lymphocyte proliferation
[42], although Stro-1 expression has also been reported
in a small population of CD34+ hematopoietic stem cells
and endothelial cells [43]. Moreover, vascular cell adhe-
sion molecule-1 (VCAM-1, CD106), a member of the
immunoglobulin superfamily which binds to the
leukocyte integrins VLA-4 and α4β7 as well as intercel-
lular adhesion molecule-1 (ICAM-1) are also markers
associated with MSC [44]. Furthermore, nestin has been
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ment usually expressed in neuronal (progenitor) cells.
Nestin-expressing MSC are predominantly found in the
bone marrow and play an important role in the mainten-
ance of a hematopoietic stem cell (HSC) niche and con-
trol of HSC homeostasis [45] (Figure 1). Whereas nestin
is associated with cell division, proliferation and mor-
phological changes, recent findings suggested that
nestin-expressing BM-MSC can differentiate into neural
cells upon exposure to an appropriate culture micro-
environment [46].
Together, the minimal characteristics of surface mar-
kers still appear to be insufficient for defining the precise
role of MSC and additional markers will be required for
determining tissue-specificity, a selective MSC subpopu-
lation, and the activation status of MSC.
Interaction of mesenchymal stromal/stem cells
and functional involvement in tissue repair, stem
cell homing and angiogenesis
A functional heterogeneity of MSC within different tis-
sue origins appears obvious and additionally, there are
also increasing evidences for functional alterations of
MSC originating from the same population [32]. These
effects are associated with the special microenvironment
surrounding each cell which is established by individual
cell-to-cell attachments and intercellular communication
processes mediated by diverse interactions with differentFigure 1 MSC functions, activation status-dependent interaction leve
phenotype following acquisition of tumorigenic compounds (DAMPs
abundant reticular cells; CAF = cancer-associated fibroblast.ECM components and by the release of cytokines or the
local exchange of microRNAs and membranous micro
vesicles [47-49] (Figure 1, Figure 2). An uptake of these
biological materials significantly influences regulatory
pathways within the corresponding MSC metabolism.
Indeed, MSC can exchange micro vesicles – also termed
exosomes - which can contain certain pre-microRNAs
[50]. MicroRNAs (miRs) represent small non-coding
RNAs of about 20 to 22 nucleotides, which, upon
sequence-specific binding to appropriate mRNAs, re-
press the translation of the corresponding proteins or in-
duce a subsequent degradation of the miR/mRNA
complexes.
Functionality of miRs in MSC
Released miR-containing exosomes into the extracellular
compartment can fuse with adjacent cell membranes as
a tool for intercellular communications and thereby,
alter cell activities in target cells. The exchange of miRs
between neighboring cells represents an integral part of
MSC communication with injured cells of damaged tis-
sue. During tissue repair and wound healing such exoso-
mal transport allows a bidirectional exchange of miRs
between injured cells and MSC. The exchange of such
regulatory compounds also contributes to reprogram the
phenotype of MSC to adapt to features of the damaged
tissues [51]. Different miRs have been proposed to play
an important role in reprogramming MSC but also inls of MSC and susceptibility to transform to an aberrant MSC
or apoptotic bodies). (CAR = related stromal-derived factor-1 (SDF-1)-
Figure 2 Interactions of activated MSC with surrounding immune cells (T cells, NK cells, dendritic cells, macrophages), endothelial cells
with concomitant angiogenesis and neo-vascularisation, extracellular matrix (ECM) components, tumor cells (e.g. breast cancer cells)
as well as damage-associated molecular patterns (DAMPs) and apoptotic bodies from necrotic/apoptotic tumor cell vesilces.
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of MSC [52]. For instance, adipogenic differentiation
was highly increased by miR105 and miR371 which was
accompanied by respective gene expression changes of
certain adipogenic key molecules including adiponectin
and fatty acid-binding protein 4. Conversely, adipogenic
differentiation of MSC can be impaired by miR-369-5p
[53]. Moreover, osteogenic differentiation of MSC can be
inhibited by miR-125b, miR-133, miR-135 and miR-206
which attenuate the expression of ERBB2 as one of the
epidermal growth factor receptors, RUNX2 (Runt-
related transcription factor 2) essential for osteoblast dif-
ferentiation and skeletal morphogenesis, Smad5 as a sig-
naling modulator of bone morphogenic proteins, and
connexin-43 as a transmembrane protein and part of
gap junctions, respectively. Likewise, expression of fur-
ther specific miRs which contribute to the regulation of
chondrogenic differentiation and pathways beyond the
mesodermal lineage interfere with the corresponding
functional alteration of MSC [52] (Figure 1).
Moreover, miRs are also involved in directing the role
of MSC in stem cells homing, particularly in keeping the
homeostasis of hematopoietic stem cells. In particular,
nestin-positive MSC and their related stromal-derived
factor-1 (SDF-1)-abundant reticular (CAR) cells contrib-
ute to hematopoietic stem cell functions within the
endo-osteal and the perivascular niche of the bone
marrow. The chemokine SDF-1 (CXCL12) which isproduced and released by CAR cells represents one of
the key players for cell migration in several tissues and
for homing of hematopoietic stem cells to the appropri-
ate bone marrow niches [54]. The capability of CAR
cells for SDF-1 production and release is strongly asso-
ciated with a constitutive down-modulation of miR-886-
3p in the cells since this miR specifically targets the 3'
untranslated region of the SDF-1 mRNA. Furthermore,
transfection of miR-886-3p into CAR cells results in the loss
of SDF-1-mediated chemotaxis [55] (Figure 1, Figure 2).
MSC interaction with macrophages
Further MSC activities in addition to the exchange of
miRs and other exosome-containing compounds include
the mutual release of chemokines and cytokines between
MSC and target cells during wound healing. For the re-
pair of damaged tissues, MSC interact with macrophages
that infiltrate the wound bed in injured epithelia. During
this process MSC can secrete factors such as MIP1α
((macrophage inflammatory protein 1-alpha), CCL3)),
and MIP2α ((macrophage inflammatory protein 2-alpha),
CXCL2, GROβ (Growth-regulated protein beta)) which
attracts pro-inflammatory M1 macrophages via their
corresponding chemokine receptors CCR1 and CXCR2,
respectively, to exhibit antimicrobial activities [56,57]
(Figure 2). Vice versa, M1 macrophages release a panel of
factors including γ-IFN, MCP-1 ((monocyte chemotactic
protein-1), CCL2)) and IL-8 which increases the mobility
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MSC can also repolarize these macrophages into anti-
inflammatory M2 macrophages. This is mediated by
γ-IFN-induced expression of cyclooxygenase in MSC fol-
lowed by enhanced production and secretion of PGE2,
whereby the MSC-mediated local increase in prostaglan-
din concentration contributes to silence the macrophage
inflammatory activity. Similarly, indoleamine 2,3-dioxy-
genase which is also inducible in MSC by γ-IFN, cata-
lyzes the conversion from tryptophan to kynurenine and
tryptophan depletion in the cellular microenvironment
inhibits the immune cell activity [59-61]. This re-
functioning of macrophages by MSC as proposed in a
model [57] further promotes wound healing (Figure 2).
MSC-induced wound healing and angiogenesis
Tissue repair and wound healing by MSC also involves
angiogenesis and neo-vascularisation which requires
interaction with endothelial cells. These interactions pre-
dominantly result in activation of the WNT/β-catenin
and Hedgehog signaling pathways while different factors
and mechanisms depend on the type of MSC tissue ori-
gin which furthermore adds to the heterogenic function-
ality of MSC e.g., MSC migrate to damaged tissue
lesions during skin repair and replace lost cells by trans-
differentiation into various skin cell types [62]. The suc-
cessful maintenance of such repair mechanisms also
necessitates angiogenesis and neo-vascularisation of the
restored tissue. Thus, other work has demonstrated that
adipose tissue-derived MSC activation of endothelial
cells and subsequent vessel morphogenesis is mediated
preferably via the serine proteases of the plasmin family
including urokinase-type plasminogen activator in con-
junction with hepatocytes growth factor and tumor ne-
crosis factor-α (TNF-α) which contribute to vessel
enlargement [63]. Whereas this activation system for
vessel invasion and elongation within the fibrin-enriched
extracellular matrix resembles that of fibroblasts, a
different set of serine proteases such as matrix
metalloproteinases are used by BM-MSC to promote
angiogenesis via local endothelial cells [64]. However,
chronic tissue damage such as chronic gastritis fol-
lowing Helicobacter pylori infection or chronic liver
injuries represent organ-associated tissue defects,
whereby aberrant changes in the microenvironment
involving biological materials and debris from nec-
rotic/apoptotic cells can derail MSC-mediated repair
processes and may result in the promotion of neopla-
sias [48,49,65] (Figure 1, Figure 2).
In sum, the population diversity of the MSC primary
cultures and the various tissue origins of the MSC popu-
lations determine their plasticity in combination with
cellular interactions, released cytokines and chemokines
and the multiple effects of miRs. Such a functionaldiversity also applies to the divergent role of MSC on
interacting cell types such as immune cells.
Interaction of MSC with immune cells for immune-
modulatory and immune-privileged functions
Some important properties of hMSC are reflected by
their functional interaction with a variety of immune-
competent cells [66]. In particular, tissue-originating
hMSC populations such as bone marrow-, adipose
tissue- or umbilical cord-derived hMSC selectively alter
immune cell functions by suppressing e.g. T cell activa-
tion or dendritic cells or by inhibiting the cytotoxic cap-
acity of natural killer (NK) cells. Thus, part of the
immune-suppressive capacity is attributed to a direct
cell-to-cell contact between hMSC and immune cells
probably through the interaction of membrane recep-
tors, adhesion molecules or the cellular exchange of
membrane vesicles. Indeed, previous work has demon-
strated that activated NK cells produce and release γ-
IFN which induces up-regulation of HLA class I on
MSC [67]. In return, HLA molecules expressed on MSC
including HLA-G increasingly bind to the inhibitory re-
ceptor ILT2 (CD85j) expressed on NK cells [68] and
subsequently contribute to the suppression of NK cell
functions by a down-modulation of activating NK cell
receptors NKp30 (CD337), NKp44 (CD336), and NKG2D
(CD314) and by inhibition of NK-cell lytic granule forma-
tion [69] (Figure 1, Figure 2).
Moreover, MSC express glycoproteins such as
galectin-1 in intracellular compartments as well as on
their cell surface which selectively inhibits T cell activa-
tion. Thus, galectin-1 knockdown in MSC partially
restores the proliferation of CD4+ and CD8+ T cells
without any detectable effects on NK cells [70]. Further-
more, cytokine-inducible levels of different adhesion
molecules including VCAM-1 and ICAM-1 are also de-
tectable on MSC which are required for a direct adhe-
sion of MSC to T lymphocytes and subsequent MSC-
mediated immunosuppression [71]. Whereas ICAM-1 and
VCAM-1 are upregulated in MSC by pro-inflammatory
cytokines such as TNFα and IL-1β in combination
with γ-IFN, these effects enable MSC to increase adhesion
to T cells. Moreover, this cell adhesion-mediated immuno-
suppression by MSC-to-lymphocyte attachment can
be significantly reversed in vitro and in vivo after in-
hibition of adhesion via specific blocking antibodies
or via adhesion molecule gene knockout [71]. These
effects underscore the necessity of a direct MSC-to-
cell interaction to convey immune suppression (Figure 1,
Figure 2).
In addition to the MSC’s adhesive capacity by inter-
active adhesion molecules, further immunosuppressive
mechanisms are relayed in part by a variety of different
cytokines and other soluble factors which are produced
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ligands (CXCL1, CXCL2, CXCL6), interleukins (IL-1, IL-
6, IL-8, IL-10, IL-11, IL-12, IL-14, IL-15), hematopoiesis-
stimulating factors (SCF, HGF, G-CSF, M-CSF, GM-
CSF), angiogenic growth factors (VEGF, VEGF-D, PlGF),
and tropic growth factors (bFGF, FGF-4, EGF, HB-EGF,
IGF-I, IGF-II, different forms of PDGF, TGF-β, TGF-β2,
TGF-β3) [72-82]. Moreover, expression of nitric oxide
synthase by MSC which can be enhanced by TNFα and
γ-IFN, is associated with increased production of nitric
oxide by MSC and inhibits T cell proliferation [83]. Fur-
thermore, cyclooxygenase as well as indoleamine 2,3-
dioxygenase (IDO) which are inducible by γ-IFN, repre-
sent synergistically acting key molecules involved in T
cell immune suppression. Cyclooxygenase metabolizes
polyunsaturated fatty acids like arachidonic acid into
prostaglandins such as PGE2 [84,85] which is involved at
least in part in the inhibition of cytokine release by T
cells [83]. The molecular mechanism of IDO is sug-
gested to act through the catalyzed conversion of trypto-
phan to kynurenine, whereby the tryptophan depletion
as well as the availability of kynurenine and further
metabolites within the hMSC microenvironment con-
tribute to suppress T cell proliferation [86,87] (Figure 1,
Figure 2).
Besides the various immune-modulatory effects of
MSC depending on the activation status and the micro-
environmental stimulation, there are also controversial
data regarding the interaction between MSC and B cells.
Studies in a mouse system have documented, that co-
culture of BM-MSC with B cells reduced the prolifera-
tive capacity and the immunoglobulin (Ig) production of
the previously LPS-stimulated immune cells [88]. More-
over, B-cell proliferation was also inhibited and IgM,
IgG, and IgA production significantly reduced by BM-
hMSC [89]. In contrast, other work has demonstrated
an increased proliferation and IgG production of B cells
after co-culturing with BM-MSC [90]. Likewise, purified
B cells which required cell-to-cell contact with MSC for
their activation, exhibited increased polyclonal prolifera-
tion and differentiation of naïve and transitional B cells
into Ig-producing cells [91].
Although precise molecular interactions still remain
unclear, how the two different actions of MSC mediate
immune-modulation, either by direct MSC-to-immune
cell attachment (e.g. via ICAM-1 and VCAM-1) or by
the release of a large panel of cytokines and micro
vesicle-containing miRs, it becomes more and more con-
ceivable that both mechanisms may be mutually com-
bined rather than representing exclusive phenomena.
Based on this hypothesis, the direct and timely limited
MSC-to-immune cell attachment could trigger and en-
hance a short-term release of required factors which
contribute to immune cell-specific (either macrophages,T-, B-, NK- or dendritic cells) responses. In addition, the
MSC-immune cell attachment establishes a close inter-
population complex which provides a minimized inter-
cellular space for maximal action of the released
cytokines and micro vesicles within this microenviron-
ment (Figure 2).
Clinical use of MSC immune-privileged properties
Besides their immune-modulatory capacity, hMSC also
possess immune-privileged properties which means that
these cells do not challenge a response of allogeneic im-
mune cells suggesting an active self-protection [92]. Due
to low expression levels of MHCI and MHCII antigens,
hMSC represent valuable prerequisites for the medicinal
use during cell or tissue transplantation. Therefore, the
significantly reduced immunogenicity favors a low rejec-
tion rate of transplantable hMSC providing a preferred
tool in regenerative medicine. However, the hMSC state
of immune privilege remains unstable in the course of
higher γ-IFN concentrations or differentiation-inducing
effects within the hMSC microenvironment which ele-
vate MHCI and particularly MHCII expression and
cause a transition from an immune-privileged to an im-
munogenic phenotype associated with the induction of
cellular cytotoxicity or immune rejection [69,93].
Taken together, hMSC represent a heterogeneous
population of stromal/stem cells originating from peri-
vascular niches of nearly all tissues which exhibit altered
proliferation and differentiation capacities, and provide
distinct levels of immune-modulatory activities [92].
This immune-suppressive potential of MSC may not
only allow their use for autologous, but also for allogen-
eic cell therapies in regenerative medicine. Moreover,
MSC also display various roles in stem cell homing and
tissue repair connected with cell differentiation, cell re-
placement, and neo-vascularisation. Although a variety
of MSC functions still remain controversial and poorly
understood, this stem cell population provides a very
promising cellular tool in the field of regenerative medi-
cine. The advantage of distinct hMSC, particularly the
ethically non-controversial populations derived from
neonatal tissues and their clinical potential are useful
prerequisites for transplantation in view of cell and/
or tissue replacement in combination with their func-
tional biodiversity [94]. Accordingly, MSC have been
successfully applied in a variety of clinical trials, e.g.
large bone defects [95] and cartilage lesions [96],
spinal cord injuries [97], cardiovascular diseases [98],
hematological pathologies [99], osteogenesis imper-
fecta [100], and graft-versus host disease [101]. How-
ever, MSC also display a large panel of interactions
with diseased cells including a variety of tumor cells
which may not always be beneficial for maintaining a
healthy microenvironment.
Hass and Otte Cell Communication and Signaling 2012, 10:26 Page 7 of 13
http://www.biosignaling.com/content/10/1/26Interaction of MSC with tumor cells and a
tumorigenic microenvironment
According to the heterogeneity of MSC functions
already observed during MSC interaction with normal
cells and particularly immune cells, there are also a var-
iety of controversial reports suggesting both, tumor-
inhibitory and tumor-promoting activities of MSC.
These conflicting observations may be related in part to
the cellular microenvironment whereby hypoxia estab-
lishes an extracellular milieu to reduce aging and enrich
poorly differentiated tumor cells and mesenchymal stro-
mal/stem cells. Such an undifferentiated hypoxic micro-
environment provides essential cellular interactions and
environmental signals for the preferential maintenance
of MSC and cancer cells [24,48,49,102].
The contradictory reports on cellular interactions be-
tween MSC and tumors can also be associated with dif-
ferent activation levels of MSC which are switched by
intracellular triggers such as different miRs. Indeed, dif-
ferent states of MSC activation are relayed by variable
expression levels of certain miR including miR-335. High
levels of miR-335 expression contribute to a potentially
non-activated (silenced) MSC state of auto-maintenance
and low amounts of miR-335 suggest an activated state
leading to proliferation, migration and differentiation in
MSC [103] (Figure 1).
Tumor-promoting effects of MSC by exosomes and MSC-
to-tumor cell contacts
Of interest, a functional role in the regulation of a neo-
plastic development and the formation of metastases has
also been attributed to miRs in breast cancer cells, par-
ticularly miR-21 and miR-205 for tumor development
and miR-126 and miR-335 for breast cancer metastases.
Whereas different amounts of miR-335 determine the
activation status of MSC, certain expression levels of this
miR also contribute to metastasis of breast cancer cells.
The constitutive expression of miR-335 targets more
than 62 genes [103] including the transcription factor
SOX4 and the extracellular matrix component tenascin
C. Thus, a down-modulation of this miR and conse-
quently, increased expression of target genes is asso-
ciated with enhanced risk of mammary tumor spreading
and formation of metastasis. Likewise, miR-126 down-
modulation is accompanied by an overall tumor growth
and proliferation [104]. Therefore, constitutive intracel-
lular amounts of these miRs are considered to exhibit
metastasis-inhibitory capabilities and consequently, tumor-
inhibitory function may be related to relevant expression
levels of additional miRs.
Tumor-promoting effects are also attributed to an
epithelial-to-mesenchymal transition (EMT), whereby
MSC play a crucial role. Thus, EMT represents a key
event for colorectal cancer progression and MSC areimplicated in this process [105]. Likewise, EMT is
involved in metastatic breast cancer. During conversion
of epithelial breast cancer cells to a mesenchymal
phenotype and loss of apical-basolateral polarity, the
tumor cells acquire morphological features and stem
cell-like characteristics as compared to MSC [106] and
may therefore resemble breast cancer stem cells. In
addition, MSC-released exosomes can induce vascular
endothelial growth factor (VEGF) expression in tumor
cells by activating extracellular signal-regulated kinase1/
2 (ERK1/2) pathway [107] which contributes to
enhanced angiogenesis and tumor growth.
Interactions of MSC with breast cancer cells include
the formation of gap junctions [108] The gap junction
represents a membrane spanning channel (connexon) on
each of the junctional cell types formed by a hexamer of
connexins and allows gap junctional intercellular com-
munication (GJIC) by transcellular exchange of low mo-
lecular weight compounds including calcium ions (Ca2+),
inositol phosphates (different IP3 and IP4) and cyclic
nucleotides Thus, a derailed GJIC or defects in GJIC can
modulate the metastatic potential of the breast cancer cells
[109]. Moreover, loss of GJIC correlates with malignant
phenotype progression in neoplastic mammary tissue
[110].
Consequently, MSC provide direct cell-cell contact
with tumor cells whereby these interactions rather than
soluble factors predominantly promote tumor cell prolif-
eration and survival in vitro [111]. Indeed, cellular inter-
actions between MSC and tumor cells are facilitated via
ICAM-1 and VCAM-1 receptors which also play a role
in normal tissues during MSC and T cell interactions.
Correlating to the presence of ICAM-1 on the MSC,
breast cancer cells express cell surface-associated mucin
1 (MUC1). MUC1 motifs can interact with ICAM-1
molecules and such ICAM-1-MUC1 interactions initiate
an actin-based cell invasive motility [112]. MUC1
(CD227, DF3, CA15-3) represents a transmembrane het-
erodimeric glycoprotein normally expressed at the apical
surface of mammary epithelium [113]. However, during
breast cancer progression, cell polarization is frequently
lost and consequently, MUC1 circumferentially distri-
butes around the entire plasma membrane of the breast
cancer cell or is highly overexpressed throughout the
cytosol [114] (Figure 2).
At the molecular level, ICAM-1-MUC1 interactions
activate Src kinase and subsequent Src-mediated phos-
phorylation of the cytoplasmic domain of MUC1 at two
highly conserved Y-x-x-P sequences (Y35VPP38 and
Y60TNP63) attribute to a direct recruitment of CrkL
binding via its SH2 domain. The SH2/SH3 adaptor pro-
tein CrkL is involved in the regulation of cell migration
through the association with guanine nucleotide ex-
change factors such as Dock180 to catalyze GTPase
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ICAM-1-MUC1-mediated Src-CrkL complex formation
further activates the small GTPases Rac1 and Cdc42
which are key effectors of the actin cytoskeleton protru-
sion machinery and thereby, reorganize the actin cyto-
skeleton and promote an actin-based cell motility [112].
Supportive studies have demonstrated, that MSC con-
tribute to alter stiffness via small GTPases Rho A and
Cdc42 [115]. Finally, the enhanced motility of the
MUC1-carrying tumor cells contributes to a significantly
elevated metastatic potential.
Tumor-inhibitory effects of MSC by ECM and soluble
factors
Together, these studies suggest that direct cell-to-cell
interactions between MSC and tumor cells via gap
junctions and the exchange of exosomes or via mem-
brane receptor assembly promote tumor cell growth.
In contrast, tumor inhibitory effects of MSC are
reported preferentially via the ECM compounds of the
microenvironment and soluble factors (Figure 2). Thus,
extracts from Wharton’s jelly-derived MSC – either
cell lysates or cell supernatants - inhibit cell growth of
a variety of cancer cell lines including breast cancer,
ovarian carcinoma, and osteosarcoma cells [116].
Moreover, β-IFN secreted by MSC within the tumor
microenvironment and intratumorally produced β-IFN
significantly reduces breast cancer growth and meta-
static potential by inactivation of the constitutive phos-
phorylation of signal transducer activator transcription
factor 3 (Stat3) via Src, and Akt kinases and a con-
comitant down-regulation of c-Myc and MMP2 ex-
pression [117]. Finally, ECM components produced by
MSC contribute to arrest the growth of metastatic
tumor cells by an up-regulation of the tumor suppres-
sor phosphatase and tensin homolog (PTEN) in the
tumor cells [98]. In addition, dickkopf (DKK1)-produ-
cing MSC are capable of inhibiting cancer cell prolif-
eration independent of the tumor-inhibitory effect of
MSC-generated ECM compounds [118].
More detailed studies in a tumor model revealed
that UC-MSC possess a significantly elevated migratory
potential as compared to BM-MSC. The capacity to
migrate towards glioma cells is accompanied by an ele-
vated expression of IL-8 receptors and CXC chemo-
kine receptors-1 and −2 on UC-MSC [119]. Malignant
glioma cells have been demonstrated to recruit MSC
by secreting angiogenic factors, such as VEGF [120],
and cytokines, including IL-8 [121]. In addition, MMPs
and the corresponding MMP tissue inhibitors are asso-
ciated with MSC migration to injured tissues [122]. In
vivo application of MSC into the contralateral hemi-
sphere of a glioma in rats was associated with migra-
tion of the MSC towards the tumor through thecorpus callosum. Moreover, intratumoral injection of
MSC resulted in a significant inhibition of tumor
growth and increased the survival of these rats [123].
In the human system, MSC integrate into gliomas after
intravascular or local injection [124]. Since MSC are
capable of homing to gliomas (likewise to other tumor
entities), these multipotent stem cells have been sug-
gested a powerful cellular vehicle to target tumor cells
[125]. In addition, the capability of MSC to release
exosomes, represents a potentially useful tool for a
specific delivery of customized anti-cancer compounds
[126,127].
In conclusion, these effects suggest that MSC dis-
play tumor-inhibitory functions preferably via the
ECM and the release of distinct factors into the
tumor surrounding microenvironment, whereas
tumor-promoting effects are relayed predominantly
by direct cell-to-cell interaction and the exchange of
membrane vesicles.
Aberrant MSC
A variety of further evidences suggest that disease- and
cancer-associated stromal cells are distinctly abnormal
as compared to MSC from healthy tissues. E.g., multiple
myeloma represents a plasma cell malignancy character-
ized by complex heterogeneous cytogenetic abnormal-
ities and a significant amount of MSC derived from
multiple myeloma carry chromosomal abnormalities and
defects in gene and protein expression [128]. Likewise,
MSC cultured from patients with severe systemic scler-
osis constitutively release higher levels of cytokines/che-
mokines such as SDF-1 and VEGF and stimulate
microvascular endothelial cell angiogenesis much more
efficiently as compared to normal BM-MSC [129]. The
development of certain sarcomas as mesenchymal
tumors has also been attributed to originate from aber-
rant MSC, whereby the WNT signaling pathway plays an
important role to exert tumor suppression and con-
versely, its inhibition is accompanied by sarcoma genesis
[130]. Moreover, growth of BM-hMSC in long-term cul-
tures (5–106 weeks) was associated with a spontaneous
malignant transformation which occurred in about half
of these cultures and demonstrated a significantly
increased proliferation rate and an altered morphology
and phenotype [131]. The close vicinity of MSC to
neighboring cells via adhesion receptors and/or the
exchange of exosomes can also favor cell fusion and
the formation of multinucleated cells which alters
MSC functionality (Figure 1, Figure 2). Previous
observations with BM-hMSC in certain neurodegen-
erative disorders and flow cytometry of fluorescently-
labeled MSC in co-culture with nucleus pulposus
cells revealed evidence for the formation of gap junc-
tions and some cell fusion although these phenomena
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tions are confirmed during co-culture of UC-hMSC
with the human breast cancer cell line MDA-MB-231
(Figure 3).
The close vicinity of MSC to the tumor entity also
enables interactions with biological material obtained
from necrotic tumor tissue and dying cancer cells. Such
necrotic factors – also termed damage-associated mo-
lecular patterns (DAMPs), can activate MSC by enhan-
cing their angiogenic capacity or affect the immune-
regulatory potential of MSC by interfering with the ex-
pression of indoleamine 2,3-dioxygenase in MSC [134].
Moreover, whole necrotic vesicles or apoptotic bodies
from dead tumor cells can be incorporated into MSC
by engulfment or fusion contributing to transform the
MSC functionality. Thus, BM-hMSC which have been
cultured in tumor-conditioned medium for up to 30d
acquire functional properties of carcinoma-associated
fibroblasts (CAF). These CAF-like transformed MSC
express myofibroblast markers, including α-smooth
muscle actin and fibroblast surface protein and pro-
duce sustained levels of SDF-1 (Figure 1, Figure 2).
Simultaneously, these CAF-like MSC also promote
tumor cell growth both, in vitro and in an in vivo co-
implantation model [135]. Likewise, MSC transformed
with specific mutations play an important role in sar-
coma genesis and in the control of sarcoma tumor
growth [136,137]. Furthermore, MSC which have been
isolated from primary breast cancer tissues significantlyFigure 3 Phase contrast/fluorescence microscopy overlay of
primary umbilical cord-derived hMSC (black arrow) and
lentivirus vector GFP- transfected MDA-MB-231 human breast
carcinoma cells (green cells) originally seeded in a ratio of
60:40 (MSC: MDA-MB-231) and co-cultured for 7d. A certain
amount of spindle-shaped MSC surrounded the tumor cells (white
arrow). However, as judged by the morphology, a small amount of
these spindle-shaped cells appeared with green fluorescence (green
arrows) which may indicate a possible fusion of MSC with GFP-
containing exosomes or a complete MSC-breast cancer cell fusion
with 2 nuclei (green arrows). Bar graph demonstrates 100 μm.promote tumor growth and size following co-
transplantation with breast cancer cells. These tumor-
derived MSC release EGF and promote mammosphere
formation via the PI3K/Akt signaling pathway [138].
Finally, MSC display some similarities to aged normal
mammary epithelial cells and tumorigenic human
breast epithelial cells particularly after EMT with re-
spect to the gene expression pattern [139] and some
surface receptor levels [140,141]. This functional asso-
ciation underscores the involvement of stem cells asso-
ciated with breast cancer and their supportive role
according to stimulatory effects from the microenvir-
onment [142, 143].
Together, MSC can directly interact with a variety
of different adjacent normal cell types either via ad-
hesion molecules and gap junctions or via exchange
of a large panel of cytokines/chemokines, exosome-
containing miRs and ECM components. In case of
tumor cells, such interactions with MSC result in the
support of tumor-promoting and tumor-inhibiting ac-
tivities, respectively. Moreover, uptake of DAMPs and
fusion with vesicles or apoptotic bodies from tumor
cells contribute to alter the MSC functionality into
an aberrant phenotype.
Conclusions
MSC demonstrate a functional heterogeneity within
different tissue origins. This heterogeneity is even dis-
played within the same population and suggests MSC
subpopulations exhibiting specialized functions accord-
ing to local tissue requirements which may develop
from certain precursor cells and still maintain stem
cell properties [144]. Thereby, MSC can maturate pre-
dominantly along phenotypes of the mesoderm lineage,
protect hematopoietic stem cells, modulate the reactiv-
ity of immune cells (e.g. macrophages, NK-, T-, B-,
dendritic cells), activate endothelial cells and either
suppress tumor growth via ECM and soluble factors
(e.g. gliomas) or enhance the motility and metastatic
capacity of tumor cells via exosome exchange and dir-
ect cell-to-cell contact (e.g. breast cancer cells). The
heterogeneity of MSC is also reflected by molecular
triggers such as cytokines or the intracellular expres-
sion levels of certain miRs that alter the MSC state of
activation in order to self-renew, maintain stemness,
regulate stem cell homeostasis, undergo differentiation,
migrate towards tissue damage, modulate immune cell
functions, support angiogenesis, and promote or inhibit
cancer growth and metastasis.
Whereas MSC appear to function almost as a cellular
all-rounder in support of tissue homeostasis and plasti-
city, these unique capabilities of biodiversity may also be
misused during transformation into aberrant MSC
phenotypes.
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